drugset / Trial / NCT00960531
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
Phase 2
Terminated
160 enrolled
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, plus QS-21 in subjects with mild to moderate Alzheimer's disease.
Timeline
- Start
- 2009-07
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vanutide Cridificar | Vaccine | 3 ug | Intramuscular |
| Subject | Vanutide Cridificar | Vaccine | 10 ug | Intramuscular |
| Subject | Vanutide Cridificar | Vaccine | 30 ug | Intramuscular |
| Background | QS-21 | Other / unclassified | 50 ug | Intramuscular |